×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu

Tag: MEM

Markets / Shares

What Have Been The Best “Hidden Gems” Webinar Performers?

July 16, 2020July 16, 2020 - by Company News

Our Hidden Gems series has provided insight into companies and industries with direct access to company CEOs. As a follow-up, we thought we would look back at our participating companies to determine the best-performing stocks post our webinars.

Read More
Shares / Video

Memphasys Ltd – ShareCafe Hidden Gems Webinar Presentation

June 29, 2020 - by Company News

Memphasys Ltd CEO and Executive Chairman Alison Coutts presents at the ShareCafe Hidden Gems Webinar on June 26, 2020. Memphasys is an Australian publicly-listed bio-separations company developing and commercialising innovative separation techniques based on the Company’s proprietary membrane technology.

Read More
Shares / Video

Memphasys – The Business Of IVF Treatments

April 16, 2020April 16, 2020 - by Company News

Read More

Shares

ASX Biotech Poised To Disrupt Global IVF Market

February 26, 2020March 17, 2020 - by Tim Boreham

ASX-listed Memphasys (MEM), has developed a novel device to separate and select sperm more quickly and effectively than the current methods. Dubbed Felix, the device uses electrical fields and membranes to sort the sperm by quality and size.

Read More
Shares / Video

Q&A With Memphasys Executive Chair Alison Coutts

July 23, 2019February 27, 2020 - by Company News

Memphasys’ Executive Chair, Alison Coutts, was interviewed at the Finance News Network Investor Event on November 29 2019. The interview and presentation can be viewed by clicking the above link.

Read More
Shares / Video

Professor John Aitken – Felix Device Interview

July 23, 2019February 27, 2020 - by Company News

Professor John Aitken, PhD, ScD, FRSE, Head of the Medical Faculty at Newcastle University, Australia, and a global leader in Assisted Reproductive Technology (ART) research is interviewed about the Felix Device and its potential application in the area of male infertility and the future needs globally of the IVF and ART industries.

Read More
Shares

Not So Fertile Ground For IVF Leader

March 13, 2019February 26, 2020 - by Tim Boreham

The flagging housing market and sagging consumer sentiment ahead of the federal and NSW elections have affected the performance of an unlikely ASX-listed exponent – the assisted reproduction outfit Virtus Health (VRT, $3.98).

Read More
  • COVID Resurgence Drags South Korean GDP to 20-Year Low
  • Disruption in 2021 and Beyond
  • Jan 2021 Australian Market Outlook: Ride Those Cyclicals
  • Asian Shares Fall on Monetary Moves, Regulatory Rumblings
  • A Bumpy and Uncertain Road to Recovery
  • Bega Now Big Cheese in Oz Food & Beverage Sector
  • Ampol Deal Looking Less Likely as Canadians Weigh Options
  • Dividend Yields Expected to Increase in 2021

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Financial Services Guide | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Cup.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Cup.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Car.